ERBB2 and prostate carcinoma: Growth factor stimulation has been reported to render AR-responsive promoters hypersensitive to androgen [6]–[14], and forced over expression of HER2/neu in androgen-dependent prostate cancer cells has been shown to drive castration-resistant growth [15], [16].